文献速递其他结缔组织病

脂肪组织来源血管基质组分治疗系统性硬化症手部病变的多中心随机试验:自体AD-SVF与安慰剂对照

Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

主要终点为基线至3个月CHFS评分变化,结果显示两组手功能均随时间改善,但AD-SVF组与安慰剂组之间无组间差异(AD-SVF组平均变化-9.2[12.2],安慰剂组-7.6[13.2]),未显示AD-SVF优于安慰剂。

要点

  • AD-SVF手指注射未在3个月时显示优于安慰剂的CHFS改善。
  • 两组手功能在3个月和6个月随访期间均随时间改善。
  • 研究样本量小,作者建议在更大规模、表型均一患者中进一步评估。

核心结论

  • AD-SVF手指注射在改善SSc患者手功能障碍方面未显示优于安慰剂。
  • 两组手功能均随时间改善,但无组间差异。

研究设计与样本

  • AD-SVF经Celution 800/CRS自动化系统处理获得,安慰剂为乳酸林格液。

主要发现

  • 主要终点基线至3个月CHFS平均变化:AD-SVF组-9.2(12.2),安慰剂组-7.6(13.2),无组间差异。
  • 6个月时两组手功能均改善。
  • 两组在年龄、性别比、病程、手部皮肤纤维化及手功能障碍主要原因方面具有可比性。

关键数值与推荐

  • 主要疗效终点为基线至3个月CHFS评分变化。
  • 次要疗效终点包括6个月CHFS评分、手功能、血管病变、手痛、皮肤纤维化、指腹敏感性、硬皮病健康评估问卷、患者与医生满意度及安全性。

临床怎么用

  • 目前证据不支持将AD-SVF手指注射作为改善SSc手功能障碍的常规治疗。
  • 临床决策时应结合本研究局限性,并与患者充分沟通证据不确定性。

局限性

  • 作者指出应考虑试验局限性,需在更大规模、表型均一且手功能障碍患者中进一步研究以准确评估AD-SVF疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the superiority of adipose tissue-derived stromal vascular fraction (AD-SVF) injection into the fingers vs placebo in reducing hand disability in systemic sclerosis (SSc) patients. METHODS: We performed a double-blind, multicentre, phase II trial from October 2015 to January 2018 in France. SSc patients with a Cochin Hand Function Scale (CHFS) ≥20/90 were randomized 1:1 to receive injection of AD-SVF or placebo. AD-SVF was obtained using the automated processing Celution 800/CRS system. The placebo was lactated Ringer's solution. The primary efficacy end point was the change of the CHFS score from baseline to 3 months. Secondary efficacy endpoints included the CHFS score at 6 months, hand function, vasculopathy, hand pain, skin fibrosis, sensitivity of the finger pulps, Scleroderma Health Assessment Questionnaire, patients and physician satisfaction, and safety. RESULTS: Forty patients were randomized. The AD-SVF and placebo groups were comparable for age, sex ratio, disease duration, skin fibrosis of the hands and main cause of hand disability. After 3 months' follow-up, hand function significantly improved in both groups with no between-group difference of CHFS (mean change of -9.2 [12.2] in the AD-SVF group vs -7.6 [13.2] in the placebo group). At 6 months, hand function improved in both groups. CONCLUSION: This study showed an improvement of hand function in both groups over time, with no superiority of the AD-SVF. Considering the limits of this trial, studies on a larger population of patients with homogeneous phenotype and hand handicap should be encouraged to accurately assess the benefit of AD-SVF therapy. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02558543. Registered on September 24, 2015.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Daumas A, Magalon J, Jouve E, et al. Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. Rheumatology (Oxford). 2022. PMID: 34297066. doi:10.1093/rheumatology/keab584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。